Robeco Institutional Asset Management B.V. Has $6.38 Million Stake in DaVita Inc. $DVA

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in DaVita Inc. by 485.5%, owning 44,809 shares valued at approximately $6.38 million as of their latest SEC filing.
• Analysts have mixed ratings for DaVita, with Bank of America downgrading its price target from $145 to $140 while Wall Street Zen upgraded it from "hold" to "buy."
• DaVita's recent quarterly earnings exceeded expectations, reporting $2.95 EPS and $3.38 billion in revenue, which is a 6.1% increase year-over-year.

Robeco Institutional Asset Management B.V. raised its stake in DaVita Inc. (NYSE:DVA - Free Report) by 485.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,809 shares of the company's stock after purchasing an additional 37,156 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.06% of DaVita worth $6,383,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. lifted its position in shares of DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares in the last quarter. National Pension Service raised its stake in shares of DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after buying an additional 84 shares during the period. Y.D. More Investments Ltd purchased a new stake in DaVita during the first quarter valued at about $35,000. NewEdge Advisors LLC lifted its stake in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock valued at $78,000 after buying an additional 88 shares in the last quarter. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of DaVita in the first quarter worth $83,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of recent research reports. Bank of America dropped their price objective on DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a report on Wednesday, September 10th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Weiss Ratings restated a "hold (c+)" rating on shares of DaVita in a research report on Saturday, September 27th. Truist Financial set a $148.00 price target on shares of DaVita in a research note on Friday, August 8th. Finally, Barclays cut their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average target price of $158.00.

DaVita Trading Down 0.8%

Shares of NYSE:DVA opened at $131.05 on Monday. The stock has a market capitalization of $9.37 billion, a P/E ratio of 12.89, a price-to-earnings-growth ratio of 0.94 and a beta of 1.13. DaVita Inc. has a 12-month low of $126.07 and a 12-month high of $179.60. The stock's 50-day moving average price is $134.81 and its 200-day moving average price is $139.96.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. During the same period in the previous year, the firm earned $2.00 EPS. The business's quarterly revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.